PHARMACEUTICAL 2017

Lunai Bioworks Inc
Rank 279 of 308



PHARMACEUTICAL 2017

Lunai Bioworks Inc
Rank 279 of 308

The relative strengths and weaknesses of Lunai Bioworks Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lunai Bioworks Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 16% points.The greatest weakness of Lunai Bioworks Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is 81%, being 164% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	732
Cost of Goods Sold	0
Intangible Assets	136
Liabilities, Current	1,508
Liabilities, Non-Current	0
Other Assets	2.6
Other Compr. Net Income	0
Other Expenses	-333
Other Liabilities	0
Other Net Income	-77
Other Revenues	43
Property and Equipment	0
Research and Development	804
Selling, General and Administrative Expense	1,230

Output Variable	Value in 1000 USD
Assets	871
Liabilities	1,508
Expenses	1,701
Revenues	43
Stockholders Equity	-637
Net Income	-1,735
Comprehensive Net Income	-1,735
BaseVar	2,100
ECR before LimitedLiability	-263%
Economic Capital Ratio	81%